| Aktienanzahl | 36,63 Mio. |
| Aktientyp | Stammaktie |
Amgen übernimmt FPRX in einem 1,9 Mrd. $ Deal
https://www.fiercebiotech.com/biotech/amgen-pays-a-premium-for-five-prime-therapeutics-a-1-9b-cash-deal
142 Mio. $ Offering
Das ist ein 1A Offering, gutes Pricing und sogar noch upsized.
"Five Prime plans to use the net proceeds of the offering, together with other available funds, to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working capital and general corporate purposes."
https://investor.fiveprime.com/news-releases/news-release-details/five-prime-announces-pricing-upsized-public-offering-common-0